Li Runting, Li Chao, Cai Zhaolun, Li Lianwang, Wei Liudong, Qian Zenghui, Zhou Dabiao
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing.
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
Medicine (Baltimore). 2020 May;99(19):e20011. doi: 10.1097/MD.0000000000020011.
Glioblastoma is the most common malignant primary brain tumor which has highly expressed vascular endothelial growth factor. To date, various antiangiogenic drugs have been investigated in clinical trials but with no overall conclusion, especially for newly diagnosed glioblastoma (nGBM). In this study, Bayesian network meta-analysis will be used to conduct a comprehensive analysis of the results of different clinical trials, and assess the efficacy of different antiangiogenic drugs on nGBM.
In order to find more comprehensive information about the application of antiangiogenic drugs in nGBM patients, we searched the MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials for relevant randomized controlled trials. We also reviewed their reference lists to avoid omissions. Cochrane risk of bias tool (V.1.4.3) and Stata (V.15.0) will be used to assess the methodological quality of this review.
This study will provide reliable evidence for different antiangiogenic therapies in nGBM patients.
We will evaluate the relative effectiveness of different antiangiogenic drugs and rank each intervention in nGBM patients through prognosis to provide decision-making reference on which method to choose for clinicians.
CRD42019146537.
胶质母细胞瘤是最常见的原发性恶性脑肿瘤，血管内皮生长因子表达较高。迄今为止，各种抗血管生成药物已在临床试验中进行了研究，但尚无总体结论，尤其是对于新诊断的胶质母细胞瘤（nGBM）。在本研究中，将使用贝叶斯网络荟萃分析对不同临床试验的结果进行综合分析，并评估不同抗血管生成药物对nGBM的疗效。
为了获取有关抗血管生成药物在nGBM患者中应用的更全面信息，我们检索了MEDLINE、EMBASE、科学网和Cochrane对照试验中央注册库，以查找相关的随机对照试验。我们还查阅了它们的参考文献列表以避免遗漏。将使用Cochrane偏倚风险工具（V.1.4.3）和Stata（V.15.0）来评估本综述的方法学质量。
本研究将为nGBM患者的不同抗血管生成治疗提供可靠证据。
我们将评估不同抗血管生成药物的相对有效性，并通过预后对nGBM患者的每种干预措施进行排名，为临床医生选择哪种方法提供决策参考。
CRD42019146537。
